metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) 3

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab

versus all
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs non active control
vs no additional treatment
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

CheckMate 914, 2017 NCT03138512

nivolumab alone (n=-9) vs. nivolumab plus ipilimumab (n=-9)

randomized controlled trial

Studied treatment

Nivolumab plus ipilimumab

Control treatment

Placebo

Patients

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

Method

double-blind

Remark

Phase 3 CheckMate -914 trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab), as adjuvant treatment of localized renal cell carcinoma or RCC, did not meet the primary endpoint.

powered by vis.js Network